Journal article icon

Journal article

XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: suitability as a biomarker for patient selection.

Abstract:

As the options for systemic treatment of malignant melanoma (MM) increase, the need to develop biomarkers to identify patients who might benefit from cytotoxic chemotherapy becomes more apparent. In preclinical models, oxaliplatin has activity in cisplatin-resistant cells. In this study, we have shown that oxaliplatin forms interstrand crosslinks (ICLs) in cellular DNA and that loss of the heterodimeric structure-specific endonuclease XPF-ERCC1 causes hypersensitivity to oxaliplatin in mammal...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1002/ijc.28454

Authors


Expand authors...
Journal:
International journal of cancer. Journal international du cancer
Volume:
134
Issue:
6
Pages:
1495-1503
Publication date:
2014-03-05
DOI:
EISSN:
1097-0215
ISSN:
0020-7136
URN:
uuid:9dfc71f4-1814-43e7-aa39-4ce284923b77
Source identifiers:
420915
Local pid:
pubs:420915

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP